120 related articles for article (PubMed ID: 38281693)
21. Preparation of a crystalline salt of indomethacin and tromethamine by hot melt extrusion technology.
Bookwala M; Thipsay P; Ross S; Zhang F; Bandari S; Repka MA
Eur J Pharm Biopharm; 2018 Oct; 131():109-119. PubMed ID: 30086393
[TBL] [Abstract][Full Text] [Related]
22. Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous suspension.
Surwase SA; Itkonen L; Aaltonen J; Saville D; Rades T; Peltonen L; Strachan CJ
Eur J Pharm Biopharm; 2015 Oct; 96():32-43. PubMed ID: 26092472
[TBL] [Abstract][Full Text] [Related]
23. Hot melt extrusion technology for improved dissolution, solubility and "spring-parachute" processes of amorphous self-micellizing solid dispersions containing BCS II drugs indomethacin and fenofibrate: Profiles and mechanisms.
Shi NQ; Wang SR; Zhang Y; Huo JS; Wang LN; Cai JH; Li ZQ; Xiang B; Qi XR
Eur J Pharm Sci; 2019 Mar; 130():78-90. PubMed ID: 30684657
[TBL] [Abstract][Full Text] [Related]
24. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin.
Ojarinta R; Heikkinen AT; Sievänen E; Laitinen R
Eur J Pharm Biopharm; 2017 Mar; 112():85-95. PubMed ID: 27888143
[TBL] [Abstract][Full Text] [Related]
25. Molecular structure and impact of amorphization strategies on intrinsic dissolution of spray dried indomethacin.
Li Y; Rantanen J; Yang M; Bohr A
Eur J Pharm Sci; 2019 Mar; 129():1-9. PubMed ID: 30553059
[TBL] [Abstract][Full Text] [Related]
26. Hot Melt Extrusion and Spray Drying of Co-amorphous Indomethacin-Arginine With Polymers.
Lenz E; Löbmann K; Rades T; Knop K; Kleinebudde P
J Pharm Sci; 2017 Jan; 106(1):302-312. PubMed ID: 27817830
[TBL] [Abstract][Full Text] [Related]
27. Whey proteins as stabilizers in amorphous solid dispersions.
Mishra J; Bohr A; Rades T; Grohganz H; Löbmann K
Eur J Pharm Sci; 2019 Feb; 128():144-151. PubMed ID: 30528387
[TBL] [Abstract][Full Text] [Related]
28. Drug-Smectite Clay Amorphous Solid Dispersions Processed by Hot Melt Extrusion.
Nandi U; Mithu MSH; Hurt AP; Trivedi V; Douroumis D
AAPS PharmSciTech; 2020 Oct; 21(7):276. PubMed ID: 33033890
[TBL] [Abstract][Full Text] [Related]
29. Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium.
Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
Int J Pharm; 2017 Jun; 526(1-2):88-94. PubMed ID: 28392278
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding.
Bahl D; Hudak J; Bogner RH
Pharm Dev Technol; 2008; 13(3):255-69. PubMed ID: 18484494
[TBL] [Abstract][Full Text] [Related]
31. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects.
Prasad D; Chauhan H; Atef E
J Pharm Sci; 2014 Nov; 103(11):3511-3523. PubMed ID: 25196860
[TBL] [Abstract][Full Text] [Related]
32. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
Greco K; Bogner R
Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
[TBL] [Abstract][Full Text] [Related]
33. Formulation of co-amorphous systems from naproxen and naproxen sodium and in situ monitoring of physicochemical state changes during dissolution testing by Raman spectroscopy.
Ueda H; Peter Bøtker J; Edinger M; Löbmann K; Grohganz H; Müllertz A; Rades T; Østergaard J
Int J Pharm; 2020 Sep; 587():119662. PubMed ID: 32682958
[TBL] [Abstract][Full Text] [Related]
34. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
35. Predicting physical stability of ternary amorphous solid dispersions using specific mechanical energy in a hot melt extrusion process.
Hanada M; Jermain SV; Lu X; Su Y; Williams RO
Int J Pharm; 2018 Sep; 548(1):571-585. PubMed ID: 30006310
[TBL] [Abstract][Full Text] [Related]
36. The influence of pressure on the intrinsic dissolution rate of amorphous indomethacin.
Löbmann K; Flouda K; Qiu D; Tsolakou T; Wang W; Rades T
Pharmaceutics; 2014 Aug; 6(3):481-93. PubMed ID: 25140536
[TBL] [Abstract][Full Text] [Related]
37. Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.
Beyer A; Radi L; Grohganz H; Löbmann K; Rades T; Leopold CS
Eur J Pharm Biopharm; 2016 Jul; 104():72-81. PubMed ID: 27130786
[TBL] [Abstract][Full Text] [Related]
38. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability.
Crowley KJ; Zografi G
J Pharm Sci; 2002 Feb; 91(2):492-507. PubMed ID: 11835208
[TBL] [Abstract][Full Text] [Related]
39. Investigation of Ethylene Oxide-co-propylene Oxide for Dissolution Enhancement of Hot-Melt Extruded Solid Dispersions.
Hurley D; Potter CB; Walker GM; Higginbotham CL
J Pharm Sci; 2018 May; 107(5):1372-1382. PubMed ID: 29410037
[TBL] [Abstract][Full Text] [Related]
40. Determination of Stable Co-Amorphous Drug-Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures.
Kissi EO; Khorami K; Rades T
Pharmaceutics; 2019 Nov; 11(12):. PubMed ID: 31771255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
